ATE444750T1 - Neurorestauration mit r(+) pramipexol - Google Patents

Neurorestauration mit r(+) pramipexol

Info

Publication number
ATE444750T1
ATE444750T1 AT06801521T AT06801521T ATE444750T1 AT E444750 T1 ATE444750 T1 AT E444750T1 AT 06801521 T AT06801521 T AT 06801521T AT 06801521 T AT06801521 T AT 06801521T AT E444750 T1 ATE444750 T1 AT E444750T1
Authority
AT
Austria
Prior art keywords
daily
pramipexole
disorders
disease
day
Prior art date
Application number
AT06801521T
Other languages
German (de)
English (en)
Inventor
James Bennett
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia filed Critical Univ Virginia
Application granted granted Critical
Publication of ATE444750T1 publication Critical patent/ATE444750T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06801521T 2005-08-15 2006-08-15 Neurorestauration mit r(+) pramipexol ATE444750T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70821305P 2005-08-15 2005-08-15
PCT/US2006/031831 WO2007022182A1 (en) 2005-08-15 2006-08-15 Neurorestoration with r(+) pramipexole

Publications (1)

Publication Number Publication Date
ATE444750T1 true ATE444750T1 (de) 2009-10-15

Family

ID=37428609

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06801521T ATE444750T1 (de) 2005-08-15 2006-08-15 Neurorestauration mit r(+) pramipexol

Country Status (10)

Country Link
US (3) US20080234338A1 (https=)
EP (1) EP1917014B1 (https=)
JP (2) JP2009504748A (https=)
AT (1) ATE444750T1 (https=)
AU (1) AU2006279643B2 (https=)
CA (1) CA2619217A1 (https=)
DE (1) DE602006009670D1 (https=)
ES (1) ES2334061T3 (https=)
IL (1) IL189512A (https=)
WO (1) WO2007022182A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
ES2432527T3 (es) * 2001-12-11 2013-12-04 University Of Virginia Patent Foundation Uso de pramipexol para tratar la esclerosis lateral amiotrófica
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
EA200700388A1 (ru) 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
HRP20100682T4 (hr) 2004-08-13 2014-08-01 Boehringer Ingelheim International Gmbh Formulacija tablete produljenog oslobađanja koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu sol, postupak njezine priprave i uporaba
WO2007022182A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
EP2497473A1 (en) * 2006-05-16 2012-09-12 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of Parkinson's disease and pharmaceutical compositions thereof
DK2101766T3 (en) * 2006-12-14 2017-01-16 Knopp Biosciences Llc Compositions and Methods for Using (R) -Pramipexole
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2681110A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
JP2010521493A (ja) * 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． （６ｒ）−４，５，６，７−テトラヒドロ−ｎ６−プロピル−２，６−ベンゾチアゾール−ジアミンの放出調節製剤およびそれらの使用方法
RU2470635C2 (ru) * 2007-05-11 2012-12-27 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
GB0721333D0 (en) * 2007-10-31 2007-12-12 Motac Neuroscience Ltd Medicaments
KR20110071064A (ko) * 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
US20120021057A1 (en) * 2009-04-09 2012-01-26 Purdue Pharma Once-daily oral ir/cr pramipexole formulation
RU2012101792A (ru) * 2009-06-19 2013-07-27 Нопп Ньюросайенсиз, Инк. Композиции и способы для лечения бокового амиотрофического склероза
KR101799429B1 (ko) 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
EP3838271B1 (en) * 2013-07-12 2025-09-03 Areteia Therapeutics, Inc. Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
WO2016194015A2 (en) * 2015-06-04 2016-12-08 Chiarugi Alberto Use of r(+)-pramipexole (dexpramipexole) for the treatment of cerebral ischemia of the focal type
IL269550B2 (en) * 2017-03-27 2025-01-01 Chase Therapeutics Corp Combining a 5HT3 antagonist and pramipexole for the treatment of synucleinopathies
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE45735T1 (de) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6156777A (en) * 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
JP3468526B2 (ja) * 1995-10-26 2003-11-17 サノフィーサンテラボ 筋萎縮性側索硬化症治療薬調製のための１−（２−ナフタ−２−イルエチル）−４−（３−トリフルオロメチルフェニル）−１，２，３，６−テトラヒドロピリジンの使用
GB9705428D0 (en) * 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
PE20000728A1 (es) * 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
WO2000006162A1 (de) * 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum
EP1126826B3 (en) * 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
AU2001278875B2 (en) * 2000-07-06 2007-06-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10037619A1 (de) * 2000-08-02 2002-02-14 Daimler Chrysler Ag Anordnung von Bedienelementen
ES2187249B1 (es) * 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
AU2001296703A1 (en) * 2000-10-06 2002-04-15 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
DE10137082A1 (de) * 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
ES2432527T3 (es) * 2001-12-11 2013-12-04 University Of Virginia Patent Foundation Uso de pramipexol para tratar la esclerosis lateral amiotrófica
WO2003077902A1 (en) * 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
JP2005526079A (ja) * 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
WO2005010011A2 (en) * 2003-07-15 2005-02-03 Xenoport, Inc. Methods of synthesis of acyloxyalkyl compounds
DE10333393A1 (de) * 2003-07-23 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
EA200700388A1 (ru) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
WO2007022182A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole

Also Published As

Publication number Publication date
WO2007022182A1 (en) 2007-02-22
IL189512A (en) 2013-03-24
ES2334061T3 (es) 2010-03-04
EP1917014B1 (en) 2009-10-07
AU2006279643B2 (en) 2010-06-17
AU2006279643A1 (en) 2007-02-22
IL189512A0 (en) 2011-08-01
JP2009504748A (ja) 2009-02-05
US20110218222A1 (en) 2011-09-08
EP1917014A1 (en) 2008-05-07
DE602006009670D1 (de) 2009-11-19
US20080234338A1 (en) 2008-09-25
US20130116292A1 (en) 2013-05-09
CA2619217A1 (en) 2007-02-22
JP2013014629A (ja) 2013-01-24

Similar Documents

Publication Publication Date Title
IL189512A0 (en) Neurorestoration with r(+)pramipexole
Papa et al. Levodopa‐induced dyskinesias improved by a glutamate antagonist in parkinsonia monkeys
CA2344407C (en) Method for the treatment of mania and bipolar disorder
RU2009126742A (ru) Композиции и способы применения (r)-прамипексола
JP2009504748A5 (https=)
FR2798065B1 (fr) Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
AU2002340971B2 (en) Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
JPH0216284B2 (https=)
CA2215923C (en) A method of treatment of mania and bipolar disorder
JP2016521755A5 (https=)
JP3942207B2 (ja) うつ性症状改善剤
JP2016528171A5 (https=)
EP0207011A2 (en) Use of some alkanoyl L-carnitines for the manufacture of a medicament for therapeutical treatment of idiopathic and induced Parkinsonism
Sukhov et al. Long-term intranasal insulin administration improves spatial memory in male rats with prolonged type 1 diabetes mellitus and in healthy rats
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
US20100168191A1 (en) Pharmaceutical formulation comprising pramipexole
US20220287994A1 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases
US5229394A (en) Method for treatment of amyotrophic lateral sclerosis comprising administration of dmp
CA3050104A1 (en) Ppary agonist for the treatment of huntington's disease
Gupta et al. Levosulpiride: A review
Buffum et al. Overdose of 2.3 grams of intravenous methamphetamine: case, analysis and patient perspective
EP3319603B1 (en) Use of methylphenidate for the treatment of gait and limb impairment secondary to pre-frontal cortex processing disorder
JP5163986B2 (ja) フェニル酪酸ナトリウムを使用する、薬物依存症又はアルコール依存症或いは躁うつ病の予防又は治療のための医薬組成物
WO2004105756A2 (en) Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof
CN120676936A (zh) 用多西环素单独或与左旋多巴组合治疗神经退行性病症

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties